Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance

• Published in: Breast cancer (Tokyo, Japan) Vol. 29; no. 6; pp. 1076 - 1087
• Main Authors: Zhu, Jing, Wu, Wenwen, Togashi, Yukiko, Taira Nihira, Naoe, Johmura, Yoshikazu, Zhu, Dajiang, Nakanishi, Makoto, Miyoshi, Yasuo, Ohta, Tomohiko
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.11.2022; Springer
• Subjects: Breast cancer; Cancer cells; Cancer Research; Health aspects; Medicine; Medicine & Public Health; Metabolites; Oncology; Original; Original Article; Surgery; Surgical Oncology; Tamoxifen; TFEB; Sacituzumab govitecan; Tamoxifen; Trop-2
• ISSN: 1340-6868; 1880-4233
• DOI: 10.1007/s12282-022-01389-3

Background Sacituzumab govitecan is an antibody–drug conjugate that delivers SN-38, an active metabolite of irinotecan, to the target molecule, trophoblast cell-surface antigen 2 (Trop-2). It is a promising drug for triple-negative breast cancer and is anticipated to be effective for luminal breast cancer. The efficacy of the agent relies on the expression of Trop-2 rather than its intracellular function. However, conditions that alter the Trop-2 expression have not been well investigated. Methods We tested a range of clinically related treatments for their effect on Trop-2 expression in cultured breast cancer cell lines. Results The expression level of Trop-2 differed among cell lines, independent of their subtypes, and was highly variable on treatment with kinase inhibitors, tamoxifen, irradiation, and chemotherapeutic agents including irinotecan. While inhibitors of AKT, RSK, and p38 MAPK suppressed the Trop-2 expression, tamoxifen treatment significantly increased Trop-2 expression in luminal cancer cell lines. Notably, luminal cancer cells with acquired resistance to tamoxifen also exhibited higher levels of Trop-2. We identified transcription factor EB (TFEB) as a possible mechanism underlying tamoxifen-induced elevation of Trop-2 expression. Tamoxifen triggers dephosphorylation of TFEB, an active form of TFEB, and the effect of tamoxifen on Trop-2 was prevented by depletion of TFEB. A luciferase reporter assay showed that Trop-2 induction by TFEB was dependent on a tandem E-box motif within the Trop-2 promoter region. Conclusions Overall, these results suggest that the effectiveness of sacituzumab govitecan could be altered by concomitant treatment and that tamoxifen could be a favorable agent for combined therapy.